Novavax vaccine protects against coronavirus in variant hot spots but proved less effective against strain in South Africa washingtonpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from washingtonpost.com Daily Mail and Mail on Sunday newspapers.
Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial
January 28, 2021 16:05 ET | Source: Novavax, Inc. Novavax, Inc.
First to Demonstrate Clinical Efficacy Against COVID-19 and Both UK and South Africa Variants
Strong efficacy in Phase 3 UK trial with over 50% of cases attributable to the now-predominant UK variant and the remainder attributable to COVID-19 virus
Clinical efficacy demonstrated in Phase 2b South Africa trial with over 90% of sequenced cases attributable to prevalent South Africa escape variant
Company to host investor conference call today at 4:30pm ET
GAITHERSBURG, Md., Jan. 28, 2021 (GLOBE NEWSWIRE) Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that NVX-CoV2373, its protein-based COVID-19 vaccine candidate, met the primary endpoint, with a vaccine efficacy of 89.3%, in its Phase 3 clinical trial conducted in the
Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial
First to Demonstrate Clinical Efficacy Against COVID-19 and Both UK and South Africa Variants
Strong efficacy in Phase 3 UK trial with over 50% of cases attributable to the now-predominant UK variant and the remainder attributable to COVID-19 virus
Clinical efficacy demonstrated in Phase 2b South Africa trial with over 90% of sequenced cases attributable to prevalent South Africa escape variant
Company to host investor conference call today at 4:30pm ET
GAITHERSBURG, Md., Jan. 28, 2021 (GLOBE NEWSWIRE) Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that NVX-CoV2373, its protein-based COVID-19 vaccine candidate, met the primary endpoint, with a vaccine efficacy of 89.3%, in its Phase 3 clinical trial conducted in the United Kingdom (UK). The study assessed efficacy during a period with high transmission and with
University of the Witwatersrand’s Professor Shabir Madhi, the lead investigator in Novavax vaccine trial, revealed during a late-night press conference on Thursday that their data showed there was a high risk for patients who had been infected by the “original” coronavirus infection to be reinfected by the mutated South African variant (aka B1.135).
After weeks of uncertainty and speculation, during a press conference just before midnight on Thursday 28 January, the lead investigator in the Novavax vaccine trial and dean of Wits University’s Faculty of Health Sciences, Prof. Shabir Madhi announced that their vaccine is the first that has shown high levels of efficacy against the B1.135 variant which causes more than 90% of all COVID-19 infections in the country, and among the study participants. Similarly, the vaccine efficacy in the UK showed high efficacy in a setting where approximately 50% of the cases were due to another variant circulating in the UK that is more transm
Another COVID-19 candidate vaccine appears to be safe and roughly 90% effective against the virus that causes the disease. It also protects against at least a few of the variants that have arisen in recent months.
On Thursday, Novavax, a Gaithersburg, Maryland-based biotechnology firm, released interim results from two clinical trials of its candidate vaccine, one in the United Kingdom and another in South Africa. A third trial, in the United States, has recruited about 13,000 out of 30,000 planned participants and won t release results for several more months.
The two-dose vaccine, temporarily called NVX-CoV2373, has been tested in nearly 20,000 people in the U.K. and South Africa, and the two studies showed it to be nearly 90% effective against symptomatic COVID-19 in the U.K., though just 50% effective in the smaller South African trial.